Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
BMC Pulmonary Medicine Open Access 26 August 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Centers for Disease Control and Prevention/Janice Car
References
Moore, A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Reports 4, 114–117 (2003).
Mygind, P.H. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975–980 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, J. The business of developing antibacterials. Nat Biotechnol 24, 1521–1528 (2006). https://doi.org/10.1038/nbt1206-1521
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1521
This article is cited by
-
Cold-adapted bacteria from a coastal area of the Ross Sea (Terra Nova Bay, Antarctica): linking microbial ecology to biotechnology
Hydrobiologia (2015)
-
Antimicrobials, drug discovery, and genome mining
Applied Microbiology and Biotechnology (2013)
-
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
BMC Pulmonary Medicine (2010)
-
A lack of drugs for antibiotic-resistant Gram-negative bacteria
Nature Reviews Drug Discovery (2007)
-
News feature: Bugs vs Drugs
Nature Medicine (2007)
